It is estimated that AI is answering around 2.5 million prompts per day – but what happens when you ask about the devastating ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

Scientists based in Australia and China have identified a pair of pesky enzymes responsible for prolonging prostate cancer – ...

Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death ...

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...